



**EMD**

Curtiss-Wright  
Electro-Mechanical Corporation  
1000 Cheswick Avenue  
Cheswick, Pennsylvania  
15024-1300  
(724) 275-5030  
Fax (724) 275-5155

P&C-07/40

L-8

2007 JUN 29 AM 11:03

RECEIVED  
REGION 1

June 27, 2007

Mark Roberts  
U.S. Nuclear Regulatory Commission, Region I  
475 Allendale Road  
King of Prussia, PA 19406-1415

**Subject: Recall of Final Status Survey Report for NRC License SNM-1120, Docket 070-01143.**

The Curtiss-Wright Electro-Mechanical Corporation (EMD) rescinds the previous submission of the Final Status Survey Report (FSSR) for Buildings 4, 5, 5D and 5F located at the Cheswick Pennsylvania facility. The March 15, 2006 letter number 06/21 provided survey data of four structures at the EMD facility. Data compiled and analyzed in this FSSR was done under the guidance of NUREG-5849. EMD rescinds this information to permit the addition of pertinent dose data to the package as required by 10CFR Part 20 Subpart E "Radiological Criteria for License Termination".

CW-EMD plans include a re-submission of the FSSR at a future date. This re-submittal will include additional information on sub-surfaces, related dose assessment of the soils, a dose assessment of the structures and the supporting survey data (FSSR). In order to abide by the current license termination regulations EMD has already begun a lengthy process of data accumulations, dose based risk analysis and report generation. Resubmission of the aforementioned report will supplement the dose analysis to satisfy current regulatory license termination requirements.

EMD has outlined a broad encompassing work plan to address the rather complex licensing situation of NRC license SNM-1120.

138669

REC'D IN LAT OCT 30 2007

NMSS/RGN1 MATERIALS-002

**Task 1: Interim Decommissioning Summary Report**

The intent is to document the radiological status of the site soils and buildings since decommissioning activities were initiated and provide a basis for planning and conducting future decommissioning activities.

**Task 2: RESRAD Analysis for all site soils North of Lemon Lane and West of Bldg. 12.**

The site specific DCGL's developed through this project will provide guidance to EMD in current and future soil remediation projects.

**Task 3: Supplemental Information for Release of Building 4, 5, 5D and 5F**

The information developed under this task is designed to support the rescinded FSSR. Upon completion of these activities the FSSR and this newly developed information will be resubmitted as a license amendment application.

RESRAD-Build Dose Assessment for Building 4, 5, 5D and 5F

Compilation of Piping Removal and Soil Survey Data for Building 4, 5, 5D and 5F

Building 4, 5D & 5F Subsurface Evaluation

Building 5 Subsurface Dose assessment and final status survey data

**Task 4: FSSR Preparation for Building 5A and 5C**

This projected submittal will be similar to the FSSR for 4, 5, 5D and 5F in that a combination of survey data analysis conducted under the guidance of NUREG-5849 will be supplemented by dose analysis.

FSS Data compilation, evaluation and reporting for Building 5A and 5C

Compilation of piping removal and soil survey data for Building 5A and 5C and soils dose assessment

RESRAD-Building Dose Assessment for Building 5A and 5C and RESRAD for sub-surface soils.

**Task 5: Interim Dose Assessment for Building 5B and 5E**

The intent is to define and document the radiological status of these two building structures as well as determine dose associated with these structures. Accessibility to specified building locations that still require survey and possible remediation is limited at this time due to current operational use of floor space.

Survey Data Compilation for Building 5B and 5E

RESRAD-Building Dose Assessment for Buildings 5B and 5E

Efforts to conduct required remediation activities at EMD continue in affected areas at the Cheswick site as they become available. Subsequent FSSR reports completed with a dose assessment will be generated as successful remediation activities are concluded.

Questions or clarifications on the information provided in this transmittal should be directed to Lisa Lamantia at (724) 275-5032 or via e-mail at [lisa.lamantia@emd.curtisswright.com](mailto:lisa.lamantia@emd.curtisswright.com).

Sincerely,



Charles T. Lim  
Manager, Regulatory Compliance